Keywords: novartis, drug, slows, gi, tumors, swiss, major

Novartis drug slows 69% of GI tumors

Article | 26 January 2009

Swiss drug major Novartis' Sandostatin LAR Depot (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuro-endocrine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Octreotide Acetate

Sandostatin

Octreotide Acetate Injection

Sandostatin LAR

Amino Acids

Go to drug listing